These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159 [TBL] [Abstract][Full Text] [Related]
24. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. Odia Y; Iwamoto FM; Moustakas A; Fraum TJ; Salgado CA; Li A; Kreisl TN; Sul J; Butman JA; Fine HA J Neurooncol; 2016 Mar; 127(1):127-35. PubMed ID: 26643807 [TBL] [Abstract][Full Text] [Related]
26. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234 [TBL] [Abstract][Full Text] [Related]
27. Irradiation and bevacizumab in high-grade glioma retreatment settings. Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162 [TBL] [Abstract][Full Text] [Related]
28. Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas. Arratibel-Echarren I; Albright K; Dalmau J; Rosenfeld MR Neurologia; 2011 Mar; 26(2):74-80. PubMed ID: 21163238 [TBL] [Abstract][Full Text] [Related]
29. Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor. Hawkins-Daarud A; Rockne RC; Anderson AR; Swanson KR Front Oncol; 2013; 3():66. PubMed ID: 23577324 [TBL] [Abstract][Full Text] [Related]
30. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Mesti T; Moltara ME; Boc M; Rebersek M; Ocvirk J Radiol Oncol; 2015 Mar; 49(1):80-5. PubMed ID: 25810706 [TBL] [Abstract][Full Text] [Related]
31. Optimal Management of Corticosteroids in Patients with Intracranial Malignancies. Dixit KS; Kumthekar PU Curr Treat Options Oncol; 2020 Jul; 21(9):77. PubMed ID: 32734428 [TBL] [Abstract][Full Text] [Related]
32. Bevacizumab at recurrence in high-grade glioma. Salmaggi A; Gaviani P; Botturi A; Lamperti E; Simonetti G; Ferrari D; Silvani A Neurol Sci; 2011 Nov; 32 Suppl 2():S251-3. PubMed ID: 21987287 [TBL] [Abstract][Full Text] [Related]
33. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. Norden AD; Drappatz J; Muzikansky A; David K; Gerard M; McNamara MB; Phan P; Ross A; Kesari S; Wen PY J Neurooncol; 2009 Apr; 92(2):149-55. PubMed ID: 19043778 [TBL] [Abstract][Full Text] [Related]
34. Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study. Shiba H; Takeuchi K; Hiramatsu R; Furuse M; Nonoguchi N; Kawabata S; Kuroiwa T; Kondo N; Sakurai Y; Suzuki M; Ono K; Oue S; Ishikawa E; Michiue H; Miyatake SI Neurol Med Chir (Tokyo); 2018 Dec; 58(12):487-494. PubMed ID: 30464150 [TBL] [Abstract][Full Text] [Related]
35. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064 [TBL] [Abstract][Full Text] [Related]
36. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591 [TBL] [Abstract][Full Text] [Related]
38. 3D conformal radiotherapy and cisplatin for recurrent malignant glioma. VanderSpek L; Fisher B; Bauman G; Macdonald D Can J Neurol Sci; 2008 Mar; 35(1):57-64. PubMed ID: 18380278 [TBL] [Abstract][Full Text] [Related]
39. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas. Yasuda T; Muragaki Y; Nitta M; Miyamoto K; Oura Y; Henmi T; Noguchi S; Oda H; Saito T; Maruyama T; Atsuchi S; Miura N; Kawamata T World Neurosurg; 2018 Jun; 114():e1138-e1146. PubMed ID: 29614360 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]